5.75 +0.16 (2.86%)
After hours: 6:38PM EST
|Bid||5.58 x 900|
|Ask||5.75 x 800|
|Day's Range||5.02 - 5.65|
|52 Week Range||2.66 - 7.35|
|Beta (3Y Monthly)||3.51|
|PE Ratio (TTM)||2.44|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 28.89% and 19.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do...
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 19.23% and 2.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Jounce Therapeutics Inc (NASDAQ: JNCE ) shares are trading higher after the company announced an amended licensing agreement with Celgene Corporation (NASDAQ: CELG ), the latter of which has agreed to ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) Akero Therapeutics Inc (NASDAQ: AKRO ) Mirum Pharmaceuticals ...
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of March 31. The results of that effort will be put on display in this article, as […]
Does the May share price for Jounce Therapeutics, Inc. (NASDAQ:JNCE) reflect what it's really worth? Today, we will...
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -22.58% and -25.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It is doubtless a positive to see that the Jounce Therapeutics, Inc. (NASDAQ:JNCE) share price has gained some 47% in the last three months. But that is meagre solace whenRead More...
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Jounce Therapeutics, Inc. (NASDAQ:JNCE) based on that […]